Skip to content
Companies

Kayak Therapeutics

TRIM7 inhibitors for RAS-driven solid tumors

Raised to date

$11.9M

of $25M offered across 1 Form D filing

Still open
$13.1M
Investors
55
Last filed
May 27, 2026

About

Kayak Therapeutics is a privately held oncology biotechnology company developing small-molecule cancer therapies against validated clinical pathways. Its lead effort targets TRIM7, an E3 ligase implicated in RTK/RAS pathway-driven tumor proliferation, with preclinical data describing activity independent of mutation status and in the setting of KRAS-inhibitor resistance. The company was founded in 2025 by Josiah Hornblower, a co-founder and former CEO of Shattuck Labs (Nasdaq: STTK), with George Fromm, PhD as scientific founder and Chief Scientific Officer. It operates out of Austin and Houston, Texas and Durham, North Carolina.

A first-in-class covalent TRIM7 inhibitor aimed at RTK/RAS-driven tumors regardless of mutation status, including tumors that have become resistant to KRAS inhibitors, and at restoring tumor-intrinsic interferon responsiveness.

Funding

  • Security to be acquiredFiled May 27, 2026Form D
    $11.9M/ $25M

Product

KT-300

Preclinical oncology therapeutic

A first-in-class covalent small-molecule inhibitor of TRIM7 in preclinical development for solid tumors driven by the RTK/RAS pathway.

  • Covalent TRIM7 inhibition
  • Activity described as independent of mutation status
  • Preclinical activity in the setting of KRAS-inhibitor resistance

Built for

Patients with RTK/RAS pathway-driven solid tumors, reached through oncologists and, prospectively, pharmaceutical partners

People on file